Axon Enterprise (NASDAQ:AXON) Price Target Raised to $725.00

Axon Enterprise (NASDAQ:AXON) had its price target upped by JMP Securities from $610.00 to $725.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have a market outperform rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued research reports about the stock. The Goldman Sachs Group boosted their target price on shares of Axon Enterprise from $500.00 to $700.00 and gave the company a “buy” rating in a report on Monday, January 27th. Needham & Company LLC boosted their price objective on Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Morgan Stanley upgraded Axon Enterprise from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $500.00 to $700.00 in a research note on Tuesday, December 3rd. Robert W. Baird lifted their target price on Axon Enterprise from $600.00 to $800.00 and gave the company an “outperform” rating in a report on Friday, December 6th. Finally, Northland Securities increased their price target on shares of Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. One equities research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $542.15.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $677.40 on Tuesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. The firm has a market cap of $51.66 billion, a price-to-earnings ratio of 175.04, a P/E/G ratio of 6.54 and a beta of 1.05. Axon Enterprise has a 52 week low of $255.68 and a 52 week high of $698.67. The firm’s 50-day simple moving average is $622.79 and its two-hundred day simple moving average is $491.30.

Insiders Place Their Bets

In other news, President Joshua Isner sold 20,000 shares of Axon Enterprise stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $606.15, for a total transaction of $12,123,000.00. Following the completion of the sale, the president now directly owns 208,166 shares in the company, valued at approximately $126,179,820.90. The trade was a 8.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Jeffrey C. Kunins sold 21,834 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $593.88, for a total value of $12,966,775.92. Following the completion of the sale, the insider now owns 154,394 shares in the company, valued at approximately $91,691,508.72. This represents a 12.39 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,545 shares of company stock worth $30,721,337 in the last three months. Corporate insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

Several institutional investors have recently made changes to their positions in AXON. Northwestern Mutual Wealth Management Co. raised its position in shares of Axon Enterprise by 30.6% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 802 shares of the biotechnology company’s stock valued at $236,000 after buying an additional 188 shares during the last quarter. Truist Financial Corp grew its stake in Axon Enterprise by 53.4% during the 2nd quarter. Truist Financial Corp now owns 6,467 shares of the biotechnology company’s stock valued at $1,903,000 after acquiring an additional 2,251 shares in the last quarter. Cetera Investment Advisers raised its holdings in Axon Enterprise by 11.8% in the 2nd quarter. Cetera Investment Advisers now owns 23,546 shares of the biotechnology company’s stock valued at $6,928,000 after acquiring an additional 2,479 shares during the last quarter. Sanctuary Advisors LLC purchased a new position in Axon Enterprise in the 2nd quarter worth approximately $836,000. Finally, Park Avenue Securities LLC boosted its holdings in shares of Axon Enterprise by 2.3% during the 3rd quarter. Park Avenue Securities LLC now owns 4,426 shares of the biotechnology company’s stock worth $1,769,000 after purchasing an additional 100 shares during the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.